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Abstract
Platinum drug-resistance in ovarian cancers mediated by anti-apoptotic proteins such as Bcl-xL is a major factor
contributing to the chemotherapeutic resistance of recurrent disease. Consequently, concurrent inhibition of Bcl-xL in
combination with chemotherapy may improve treatment outcomes for patients. Here, we develop a mathematical model to
investigate the potential of combination therapy with ABT-737, a small molecule inhibitor of Bcl-xL, and carboplatin, a
platinum-based drug, on a simulated tumor xenograft. The model is calibrated against in vivo experimental data, wherein
xenografts established in mice were treated with ABT-737 and/or carboplatin on a fixed periodic schedule. The validated
model is used to predict the minimum drug load that will achieve a predetermined level of tumor growth inhibition,
thereby maximizing the synergy between the two drugs. Our simulations suggest that the infusion-duration of each
carboplatin dose is a critical parameter, with an 8-hour infusion of carboplatin given weekly combined with a daily bolus
dose of ABT-737 predicted to minimize residual disease. The potential of combination therapy to prevent or delay the onset
of carboplatin-resistance is also investigated. When resistance is acquired as a result of aberrant DNA-damage repair in cells
treated with carboplatin, drug delivery schedules that induce tumor remission with even low doses of combination therapy
can be identified. Intrinsic resistance due to pre-existing cohorts of resistant cells precludes tumor regression, but dosing
strategies that extend disease-free survival periods can still be identified. These results highlight the potential of our model
to accelerate the development of novel therapeutics such as BH3 mimetics.
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Introduction
Although ovarian cancer accounts for only 3% of cancers in
women, it is the fifth most common cause of cancer death in
women in the developed world [1]. Primary treatment for
advanced ovarian cancer consists of cytoreductive surgery followed
by adjuvant chemotherapy. The chemotherapeutic regimen
typically combines a taxane such as paclitaxel with a platinum-
based drug such as carboplatin, which causes cell death by
inducing DNA damage. While patients initially respond well to
therapy, most ultimately relapse, with recurrent disease being
associated with progressive resistance to platinum-based therapy
[2,3]. Consequently, 5-year survival rates for women with
advanced ovarian cancer are only 30–40% [4].
Several factors may contribute to platinum drug-resistance (for a
comprehensive review, see [5,6]). Here, we are concerned with the
contribution of the anti-apoptotic protein Bcl-xL to drug-
resistance. Bcl-xL belongs to the Bcl-2 family of intracellular
proteins that regulates programmed cell death, or apoptosis [7].
Previous studies have revealed a significant correlation between
Bcl-xL expression and carboplatin-resistance [8–10], and in-
creased sensitivity to standard chemotherapeutic agents of ovarian
cancer cell lines when Bcl-xL expression is inhibited [11–13].
Therefore, concomitant inhibition of Bcl-xL in combination with
adjuvant chemotherapy may improve treatment outcomes for
ovarian cancer patients.
In [13], Witham et al. assess the therapeutic potential of treating
ovarian cancer that express Bcl-xL with carboplatin and ABT-737,
a small-molecule inhibitor of Bcl-xL. Results from in vitro cell
proliferation assays revealed synergistic inhibition of cell-growth
and more rapid apoptosis when carboplatin was combined with
ABT-737, than when it was administered as a single agent.
Further, the times at which the two drugs are administered were
also shown to be an important determinant of therapy efficacy,
with an ABT-737 dose immediately following carboplatin found to
yield the greatest extent of cell death. To understand better these
experimental findings, we have previously developed a biochem-
ically-motivated model for the growth of in vitro ovarian cancer
[14], that was validated against available experimental data. A key
prediction of our model is that the experimentally observed
synergy between ABT-737 and carboplatin is due to the increased
dependence of DNA-damaged cells intracellular Bcl-xL.
Here, we develop a mathematical model of ovarian cancer
xenograft growth to test the efficacy of combining ABT-737 and
carboplatin for the treatment of ovarian cancers growing in vivo.
While models of cancer therapy involving platinum-based
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compounds [15,16] or drugs targeting the Bcl-2 family [17,18]
have been proposed, to the best of our knowledge this is the first
attempt to model the effect of a combination of these drugs on
tumor growth. We carefully account for the pharmacodynamics of
both drugs. Further, since the active processing of administered
drugs by the body may have a significant effect on their efficacy
and how they interact, we also need to incorporate the
pharmacokinetics of carboplatin and ABT-737 in our model.
The model is parametrized using experimental data reported in
[13], wherein monoclonal ovarian tumor xenografts established in
mice were treated with fixed doses of carboplatin and ABT-737
administered periodically and time-courses of tumor growth
inhibition recorded. The validated model is then used to identify
dosing strategies for the treatment of monoclonal tumors, which
either lead to fastest times to minimal residual disease or minimize
total drug load to achieve a predetermined level of tumor growth
inhibition. The infusion time of carboplatin doses is predicted to
be an important determinant of the long-term response of tumors
to therapy, this testable prediction underscoring the practical
significance of our results.
As mentioned earlier, a major cause of long-term treatment
failure in ovarian cancer patients is the emergence of carboplatin-
resistance. Given its synergistic action with carboplatin, ABT-737
co-therapy has the potential to prevent or delay treatment failure.
We investigate this potential in the case when resistance to
carboplatin is driven by genetic or epigenetic aberrations. Such
aberrations arise in two different ways. In acquired resistance, genetic
mutations emerge after the administration of chemotherapy, as a
result of a failure in DNA repair in cells treated with carboplatin.
Alternatively, in intrinsic resistance, a small population of resistant
cells may already be present before the administration of
chemotherapy. By distinguishing between these alternative
scenarios of drug resistance, our model represents a useful tool
with which to design individualized treatment protocols targeted
against carboplatin-resistance.
Results
Our model of ovarian cancer xenograft growth and its response
to carboplatin and ABT-737 therapy can be described in
mathematical terms by a coupled system of ordinary and partial
differential equations (further details are included in the Section S1
in File S1), which govern the temporal dynamics of the following
key variables: the numbers of proliferating and arrested cancer
cells; the concentrations of carboplatin and ABT-737 in circula-
tory and cancer tissue/intracellular compartments; and the
intracellular concentrations of two members of the Bcl-family
(Bcl-xL and Bax). A schematic detailing the response of the cancer
cells to therapy is shown in Figure 1A, while Figure 1B depicts
intracellular reactions between ABT-737 and Bcl-family proteins.
We calibrate our model by fitting time-course tumor xenograft
growth inhibition data taken from [13], wherein ovarian cancer
(IGROV-1 cell) xengrafts were established in mice and treatment
in the form of 30 mg/kg carboplatin administered weekly, or
100 mg/kg ABT-737 administered daily, or a combination of
both, started 19 days post-transplantation. The results of these fits
are plotted in Figure 1. Following model calibration, a series of
numerical experiments are carried out to identify dosing strategies
that exploit the synergy between carboplatin and ABT-737. Since
our model formulation is based on experiments that studied the
response of monoclonal xenografts to therapy, we start by
considering a tumor that comprises a homogenous population of
carboplatin-sensitive cells. A major aim of our model is to
investigate the potential of co-treatment with ABT-737 to prevent
or delay the onset of carboplatin-resistance that is a leading cause
of treatment failure. We therefore also simulate the treatment of a
tumor that consists of carboplatin-sensitive and -resistant cells. The
emergence of resistance under two distinct scenarios is considered:
(i) acquired resistance resulting from faulty DNA damage repair;
and (ii) intrinsic resistance resulting from a pre-existing population
of resistant cells.
Following [13], in all simulations carboplatin is assumed to be
administered on a weekly schedule and ABT-737 on a daily
schedule. When simulating monoclonal xenograft treatment, the
initial number of tumor cells is calculated from the size of tumors
at the initiation of therapy. As can be seen from the cell number
time-courses in Figure 1D, the weekly administration of carbo-
platin induces oscillations in tumor size. Therefore, cell numbers
averaged over the period of carboplatin administration (7 days) are
used to make quantitative comparisons between tumor responses
to various treatment strategies (see Figures 2–5). Tumors are
assumed to have achieved a steady-state average size if the relative
change in average tumor cell numbers between successive weeks is
less than 0.001% and time to minimal residual disease (Tm) is
defined as the period for which therapy must be administered so
that the average number of cells is less than 1.
Optimal Relative Doses for Monoclonal Tumors
We consider the following optimization problem in the
treatment of cancers with a combination of two or more drugs –
‘‘What drug doses achieve a predetermined level of cell kill while
minimizing patient drug load?’’
For illustrative purposes, we use our model to predict the
optimal doses of carboplatin and ABT-737 required to achieve a
67% growth inhibition in monoclonal tumors at the end of 4 weeks
of therapy (that is, the treatment time reported in [13]). Note that
minimizing the drug load is equivalent to minimizing the
Combination Index (CI) of the two drugs, defined as
CI67~(C=C67)z(A=A67) [19], subject to the constraint that 4
weeks post-therapy, tumor size is 33% of its untreated value. Here,
C67 and A67 are the amounts of drugs required to achieve a 67%
growth inhibition when administered as single-agents, C is the
weekly bolus dose of carboplatin and A is the daily bolus dose of
ABT-737 when these drugs are used in combination. C is varied
between 0 and C67, and the constraint used to generate values of
A. This represents an optimization problem for the function CI67
in a single variable C that assumes values on a closed and bounded
interval and, hence, CI67 attains its minimum therein.
A phase diagram of the drug doses required to inhibit tumor
growth by 67% after 4 weeks is shown in Figure 2A, with ABT-
737 doses plotted along the abscissa and carboplatin doses plotted
along the ordinate. CI67 values for various dose combinations are
enumerated along the curve. A weekly bolus of 17.8 mg/kg
carboplatin combined with a daily bolus dose of 86.5 mg/kg ABT-
737 is predicted to minimize the CI67 (dashed lines). We remark
that similar curves can be computed for other levels of tumor
growth inhibition at the end of a fixed time period, and for other
treatment strategies. The tumor cell time-course data correspond-
ing to these optimal doses presented in Figure 2B reveal that the
levels of tumor growth inhibition after 4 weeks of treatment with
either 86.5 mg/kg ABT-737 administered as a single agent or
17.8 mg/kg carboplatin administered weekly as a single agent are
31.4% and 28.9% respectively. The predicted level of growth
inhibition when these doses are combined is 67%.
Simulating treatment for periods longer than 4 weeks with drug
doses fixed at the above values further underscores the synergy
between the two drugs. Figure 2C shows that if the tumor is
allowed to reach its (average) steady state size, the levels of tumor
Carboplatin and ABT737 Therapy for Ovarian Cancer
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growth inhibition decrease to 31.7% and 23.1% when ABT-737
or carboplatin are applied as monotherapy, respectively, whereas
combination treatment results in a 79.2% tumor growth inhibition
in the long term.
Optimal Dose Scheduling for Monoclonal Tumors
We next use our model to identify an optimal dose-delivery
strategy when monoclonal tumors are treated with a combination
of ABT-737 and carboplatin for long times. Following the
experimental protocol in [13], the doses of carboplatin and
ABT-737 are fixed at 30 mg/kg and 100 mg/kg, respectively. In
particular, the dependence of tumor response on two key
parameters, the carboplatin infusion time Ti, and the sensitivity
rs of arrested cells to changes in intracellular Bax, is investigated.
With rs fixed at its baseline value (rs~135), steady-state values
of average cell number are calculated as Ti varies between 0 hours
(bolus dose) and 120 hours. Figure 3A reveals that minimal
survival of tumor cells is predicted for 1ƒTiƒ25. If Tiv1 hour,
even though significant levels of long-term tumor growth
inhibition can be achieved (see inset), complete remission is not
possible. Additionally, for Tiw25 hours, the level of growth
inhibition decreases rapidly as Ti increases. In Figure 3B, we show
how Tm, the length of time for which treatment must be
administered in order to achieve minimal survival of tumor cells
varies when 1ƒTiƒ25. As Ti increases from Ti~1,Tm decreases,
attaining a minimum of 215 days when carboplatin is adminis-
tered via weekly infusions lasting 8 hours, and then increases for
larger values of Ti.
Tm depends not only on the carboplatin infusion time Ti, but
also on rs, the sensitivity of arrested cells to changes in
intracellular Bax. For each value of rs between 0 and 600, the
minimum of Tm is calculated as Ti is varied between 0 and
120 hours. Figure 3C shows that this minimum decreases rapidly
as rs increases from rs~0, plateauing at a value of 215 days for
large values of rs. In all considered cases, Tm attains its minimum
for Ti~8 hours (data not shown).
Emergence of Acquired Resistance
We now investigate the potential of ABT-737 co-therapy to
prevent or delay the emergence of carboplatin-resistance. Since
Figure 1. Model schematic and fits to experimental data. A, Model schematic. Ovarian cancer cells, N(t) proliferate and undergo apoptosis at
a rate dependent on intracellular Bax concentration. Administration of carboplatin induces DNA damage, leading to cell cycle arrest. Arrested cells,
M(t,a) subsequently undergo apoptosis at a rate proportional to the amount of DNA damage sustained at the time of arrest and on their intracellular
Bax concentration, and may also recover to the proliferating population. The rates at which N andM undergo cell death are elevated on application
of ABT-737, which leads to increased levels of intracellular Bax. B, Intracellular reaction diagram of the heterodimerization reaction between Bcl-xL (B)
and Bax (X ) molecules, and the inhibition of Bcl-xL by intracellular ABT-737 (AC). C, D, Fit to time-course tumor xenograft growth inhibition data
taken from [13]. Briefly, ovarian cancer (IGROV-1 cell) xengrafts were established in mice and treatment started 19 days post-transplantation. Levels of
tumor growth inhibition were recorded periodically. Experimental data is represented by black squares and red triangles, while solid curves show
best fits. Values represent mean and standard deviation (from experimental data). C, Weekly treatment with vehicle (black squares and curve) or daily
treatment with 100 mg/kg of ABT-737 (red triangles and curve). D, Weekly treatment with 30 mg/kg carboplatin (black squares and curve) or a
combination of carboplatin and ABT-737 (red triangles and curve).
doi:10.1371/journal.pone.0081582.g001
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ovarian cancers are frequently diagnosed at a late stage [20], we
simulate the application of therapy to tumors that have already
attained their maximal untreated size (carrying capacity). As
several carboplatin-sensitive and resistant ovarian cancer cell lines
Figure 2. Optimizing carboplatin and ABT-737 doses when
given in combination. A, Predicted Combination Index (CI) values
computed for a desired tumor growth inhibition level of 67%, for
various combinations of carboplatin and ABT-737. Following the
experimental protocol in [13], treatment is initiated at 19 days post-
transplantation and continued for 4 weeks. Simulations indicate that a
combination of 17.8 mg/kg carboplatin given weekly combined with a
daily dose of 86.5 mg/kg ABT-737 minimizes the CI and hence
maximizes the synergy between the two drugs (dashed lines). B,
Predicted tumor growth dynamics corresponding to the optimal dose
combination found above. Plots show tumor cell numbers averaged
over 7 days (the period of carboplatin administration) versus time. C,
Predicted time-courses of tumor growth inhibition levels as compared
to the control (no treatment) case, corresponding to the optimal dose
combination found above.
doi:10.1371/journal.pone.0081582.g002
Figure 3. imulations showing long-term tumor xenograft
response to combination therapy. Following the experimental
protocol in [13], the administration of a weekly dose of 30 mg/kg
carboplatin together with a daily dose of 100 mg/kg ABT-737 is
simulated, and simulations allowed to run until tumor cell numbers
averaged over 7 days (the period of carboplatin administration) achieve
a steady-state. A, Predicted steady states of average tumor cell
numbers as a function of carboplatin infusion time Ti . As Ti is
increased from 0 hours (corresponding to a bolus dose) to 120 hours,
the average tumor cell number steady-state decreases rapidly to v1
(see inset), and then increases, with minimal survival of tumor cells
predicted for 1ƒTiƒ25. B, Predicted values of Tm , the length of time
therapy must be administered to achieve minimal residual disease
(defined asv1 cell remaining) as Ti is varied between 1 and 25 hours.
A minimum value of Tm~215 days is predicted for weekly carboplatin
infusions lasting 8 hours. C, Minimum values of Tm are predicted to
decrease to 215 days as rs , the arrested cell sensitivity to intracellular
Bax is increased. In all cases, a carboplatin infusion time of 8 hours
minimized the cure time.
doi:10.1371/journal.pone.0081582.g003
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have been shown to have similar sensitivity to ABT-737 [13],
carboplatin-sensitive and -resistant tumor cells are assumed to be
equally sensitive to ABT-737 in our model.
We first assume that there is a small probability that cells
recovering from a carboplatin-induced state of arrest experience
DNA damage, resulting in a resistant phenotype. We assume
further that no resistant cells exist at the start of treatment.
Figure 4A–D shows predicted average cell number time-courses
for a tumor treated with increasing weekly bolus doses of
carboplatin only. A weekly dose of 1300 mg/kg is required to
affect a cure and prevent the emergence of resistance (Figure 4D).
Smaller doses result in transient decreases in tumor size, with the
tumor eventually recovering to its untreated size (Figure 4A–C)
due to the dominance of resistant cells. In contrast, Figure 4E
reveals that a weekly bolus dose of 30 mg/kg carboplatin
combined with a daily dose of 100 mg/kg ABT-737 may prevent
the onset of carboplatin-resistance and result in tumor-growth
control at 6.5% of its untreated level at steady-states. Significantly,
the same combination, with carboplatin administered as an 8-hour
infusion instead of as a bolus, is predicted to result in tumor
remission within 150 days of treatment (Figure 4F).
Optimal Dose Scheduling for Monoclonal Tumors
Finally, we consider the response of a tumor which contains a
small population of carboplatin-resistant cells at the start of
treatment. Figure 5A–C shows predicted average cell number
time-courses when the tumor is treated with increasing weekly
bolus doses of carboplatin alone. Now, even doses in excess of
1300 mg/kg (Figure 5C) are unable to induce sustained tumor
regression. Further, in contrast to the case of acquired resistance, a
weekly bolus dose of 30 mg/kg carboplatin combined with a daily
dose of 100 mg/kg ABT-737 is unable to prevent the onset of
carboplatin-resistance (Figure 5D), with the tumor recovering to
65.2% of its untreated size after a transient decline in cell
numbers. Figure 5E shows that administering carboplatin as an 8-
hour infusion results in the tumor reaching a much lower
minimum at around day 150 of treatment, indicating a possible
period of disease-free survival, defined as clinically undetectable
disease. However, resistant cells eventually dominate and the
tumor escapes from therapy-induced growth control. Increasing
the daily ABT-737 dosage to 500 mg/kg in combination with
30 mg/kg carboplatin given as a 8-hour infusion is predicted to
increase the disease-free survival time, and lead to a greater level of
long-term growth control (Figure 5F).
Discussion
The development of carboplatin-resistance is a major factor
hampering the successful treatment of ovarian cancer with
standard chemotherapy (carboplatin+paclitaxel). This resistance
may be mediated in part by members of the Bcl-2 family that
regulate cellular apoptosis. Consequently, it has recently been
Figure 4. The emergence of acquired resistance to carboplatin therapy. DNA-mismatch repair in arrested cells recovering to the
proliferating population is assumed to be the cause of resistance. The treatment of a late-stage tumor is simulated. Plots show 7 day-averages of
carboplatin-sensitive (blue curve), carboplatin-resistant (red curve) and total (dashed black curve) tumor cell numbers versus time, as treatment
strategy is varied. In all cases, therapy is administered for a period of 1 year. Increasing the weekly bolus dose of carboplatin administered as a single
agent from A, 30 mg/kg, B, 300 mg/kg, to C, 800 mg/kg, cannot prevent the emergence of carboplatin-resistance. D, In fact, a weekly dose of
1300 mg/kg carboplatin is required to induce tumor regression. E, A combination of 30 mg/kg carboplatin delivered weekly as a bolus together with
100 mg/kg ABT-737 delivered daily is predicted to prevent the emergence of resistance and lead to tumor growth control at 6.5% of pre-treatment
levels. F, The same combination dose, with carboplatin delivered via a 8-hour infusion is predicted to induce tumor regression within 150 days.
doi:10.1371/journal.pone.0081582.g004
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proposed [13] that inhibiting anti-apoptotic proteins such as Bcl-
xL may improve the efficacy of carboplatin. A critical challenge in
the development of such novel therapeutics is to arrive at
treatment strategies that maximally exploit any synergy between
the drugs, and to identify patients who might benefit from such a
combination.
In this article, we have presented a mathematical model of the
growth of an ovarian cancer xenograft and its treatment with
carboplatin, and ABT-737, a small molecule inhibitor of Bcl-xL.
The main goal of this research was to identify protocols for the
treatment of ovarian cancer in vivo that exploit the molecular basis
of synergy between the two drugs. To this end, we explicitly
incorporated the intracellular regulation of apoptosis by the Bcl-2
family of proteins, and introduced a cell-age structured model to
simulate the effect of carboplatin on cell fate. Further, to reflect the
in vivo setting, detailed pharmacokinetics of carboplatin and ABT-
737 were also included. The model was validated by fitting time-
courses of ovarian cancer xenograft growth inhibition reported in
[13]. The good agreement between model simulations and
experimental data give confidence that the model is able
accurately to describe the underlying biology.
We first simulated the treatment of tumors that consist of a
monoclonal population of cells. Doses of carboplatin and ABT-
737 required for a certain level of tumor growth inhibition were
calculated, which minimize patient drug load and hence maximize
the synergy between the two drugs. The method we describe here
can in principle be applied to any drug combination and can easily
be tailored to account for side effects of the drugs under
evaluation, once appropriate data is available to support the
model. Using our approach, physicians can estimate the impact of
different doses of drugs in combination on the therapeutic
response of patients. As combination therapies are increasingly
being applied in oncology, models such as the one we present here
can lead to significant time and cost savings by minimizing the
choices that need to be examined experimentally. Further, such
modeling can also be used to arrive at optimal individualized
treatment strategies for evaluating combinations of chemothera-
peutic drugs in clinical trials.
An equally important application of the model is predicting the
long-term response to therapy. An exhaustive search of parameter
space revealed a control parameter that is predicted to be a critical
determinant of tumor growth dynamics when prolonged admin-
istration of carboplatin and ABT-737 co-therapy is simulated. This
is the infusion time of the weekly dose of carboplatin. Carboplatin
is typically administered as an infusion lasting 15 minutes or more
when given in combination with paclitaxel. In fact, it has been
proposed that the efficacy of carboplatin is directly linked to its
AUC (Area Under the Curve) value, and the Calvert formula
Figure 5. Intrinsic resistance to carboplatin therapy. A small fraction (1 in 60,000) of carboplatin-resistant cells is assumed to be present prior
to treatment initiation. The treatment of a late-stage tumor is simulated. Plots show 7 day-averages of carboplatin-sensitive (blue curve), carboplatin-
resistant (red curve) and total (dashed black curve) tumor cell numbers versus time, as treatment strategy is varied. In all cases, therapy is
administered for a period of 1 year. Increasing the weekly bolus dose of carboplatin administered as a single agent from A, 30 mg/kg, B, 600 mg/kg,
to C, 1300 mg/kg, cannot prevent the onset of carboplatin-resistance, with overall tumor size returning to pre-treatment levels eventually. D, E, F, In
fact, a combination therapy of 30 mg/kg carboplatin delivered weekly as a bolus (D) or via 8-hour infusion (E, F) together ABT-737 delivered daily at a
dose of 100 mg/kg (D, E) or 500 mg/kg (F) is also unable to prevent the emergence of resistance. However, combination therapy is predicted to
result in partial tumor growth control, with a steady-state tumor size reaching 65.2% of pre-treatment levels for a combination of 30 mg/kg
carboplatin and 100 mg/kg ABT-737 (D, E). Increasing ABT-737 dosage to 500 mg/kg is predicted to induce extended periods of disease-free survival,
as evidenced by a dip in the total tumor size graph (F).
doi:10.1371/journal.pone.0081582.g005
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currently used to determine its clinical doses makes use of this fact
[21]. However, our model simulations suggest that when
combined with ABT-737, the efficacy of combination therapy is
determined not only by the AUC of carboplatin, but also by the
duration of drug infusion. Our simulations predict that weekly
carboplatin infusions lasting between 1 and 25 hours combined
with daily doses of ABT-737 result in the minimal survival of
tumor cells. This is because, when administered as a rapid
infusion, the peak tissue concentration of carboplatin is high, and a
high level of DNA damage is induced in cancer cells from which
they are unlikely to recover, irrespective of changes in intracellular
Bcl-xL levels. Consequently, the synergy between the carboplatin
and ABT-737 is muted. Equally, slower infusions of carboplatin
result in extremely low tissue concentrations of the drug, so that
the level of DNA damage induced in cells is minimal, and even
with inhibited Bcl-xL levels, arrested cells are likely to recover to
the proliferating pool. Note that since ABT-737 was simulated to
be administered daily and has a slow clearance rate, its
intracellular concentration rapidly achieves a non-zero mean (see
Figure S2D). Therefore, changing the infusion time of ABT-737
administration is not predicted to alter our predictions.
Further, numerical simulations were carried out to identify the
carboplatin infusion time that results in the fastest time to minimal
residual disease. These times were observed to decrease rapidly to
a minimum value as the sensitivity of arrested cells to intracellular
Bax concentration (rs) was increased. The parameter rs is a
quantitative measure of the synergy between the carboplatin and
ABT-737 and can be important in identifying a subclass of patients
who would most benefit from such a combination of drugs.
However, ?s cannot be directly measured from experiments. As
demonstrated here, we can infer its value by fitting model
simulations to tumor xenograft growth inhibition data when both
drugs are given in combination.
ABT-737 co-therapy is now being developed to improve the
efficacy of carboplatin, and may aid in delaying the onset of
chemoresistance in ovarian cancers. We therefore investigated the
therapeutic potential of combinations of ABT-737 and carboplatin
to treat ovarian cancers in which carboplatin-resistance arises in
two distinct scenarios. Genetic mutations leading to resistance may
be acquired as a result of faulty DNA damage repair when cells try
to recover from carboplatin administration. Carboplatin-resistance
may also be an intrinsic property of the cancer, stemming from
resistant cells present when treatment starts. A key strength of our
approach is the ability to distinguish between these scenarios. For
instance, in the case of acquired resistance, model simulations
predicted that preventing cells that have undergone carboplatin-
induced DNA-damage from recovering and returning to the
proliferating population precludes the emergence of resistance.
However, the amount of carboplatin required to achieve this as a
single-agent may be toxic for the host and thus not feasible. In
contrast, combination therapy at low doses, with carboplatin
administered optimally as described earlier, is sufficient to prevent
the onset of resistance. When resistance to carboplatin is intrinsic,
tumor remission is no longer feasible, but our model can be
applied to identify dosing strategies that extend periods of disease-
free survival. It has been proposed that the development of
chemoresistance may result from insufficient exposure of tumor
cells to drugs [22], and our simulations further accentuate the
dangers of under-treatment.
The model presented in this article has the potential to
accelerate the translation from bench-to-bedside of novel thera-
peutics such as ABT-737, and to reduce the costs associated with
drug development. However, the eventual clinical application of
our model will require the validation of its predictions with further
experiments. For instance, tumor xenograft growth inhibition
experiments with varying doses of carboplatin and ABT-737
alone, and in combination would be extremely helpful in fine-
tuning the functional responses of cancer cells to therapy.
Measuring the relative constitutive expression levels of the Bcl-2
family would improve the accuracy of the quantitative description
of the ABT-737-targeted intracellular apoptosis pathway. Detailed
pharmacokinetic studies of ABT-737, which include the temporal
dynamics of its intracellular concentration, would help in a better
parameterization of our model. Finally, experimentally validating
our model predictions relating to the optimal time of infusion of
carboplatin when co-administered with ABT-737 could constitute
a significant breakthrough in the treatment of ovarian cancers, and
solid tumors in general.
A limitation of our approach is that while we have incorporated
carboplatin-resistance by simulating a completely resistant cell
line, in practice a human tumor may contains many different
populations of cells with varying levels of resistance to carboplatin,
and sensitivities to ABT-737. Further, resistance to therapy can
arise from multiple mechanisms. Consequently, in future versions
of our model we will incorporate a greater diversity of cellular
phenotypes. We also plan to include the administration of
paclitaxel as a third drug in the combination chemotherapy of
ovarian cancers, and replace ABT-737 with ABT-263, its orally
available analogue currently under phase I clinical trials for the
treatment of a number of solid tumors [23,24].
Finally, the work presented here illustrates how mathematical
modeling has the potential to support the preclinical and clinical
development of novel cancer therapeutics. There are numerous
parameters that affect the outcome of drug evaluation, and it may
not be feasible to address all of these experimentally. Quantitative
modeling represents a powerful resource to optimize the likelihood
of the successful development of targeted therapies.
Materials and Methods
Model Foundation
our model of ovarian cancer xenograft growth and treatment
consists of a coupled system of ordinary and partial differential
equations (full model equations are listed in section S1 in File S1),
which govern the temporal dynamics of the following key
variables: N(t) and M(t,a), the numbers of proliferating and
arrested cancer cells (in millions) respectively; Cperit(t), CP(t) and
CT (t), the concentrations in mM of intraperitoneal, plasma and
tissue carboplatin respectively; Aperit(t), AP(t) and AC(t), the
concentrations in nM of intraperitoneal, plasma and intracellular
ABT-737 respectively; and B(t), X (t), Q(t) and P(t), the
intracellular concentrations in nM of Bcl-xL, Bax, Bcl-xLBax
complex and Bcl-xLABT-737 complex respectively. Here, time t is
measured in days, and a is a time-like variable, representing the
period of time a cell has spent in a growth-arrested state. A
schematic detailing the response of the cancer cells to therapy is
shown in Figure 1A. In the sections that follow, the principles
underlying our model formulation are introduced.
Dynamics of Proliferating Cells
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The growth rate of untreated tumor xenografts is typically
exponential at early times, and plateaus as they become larger
[25]. Consequently, we assume that ovarian cancer cells grow
logistically in the absence of treatment, with growth rate lN and
carrying capacity K . We remark that models of periodic
chemotherapy based on the logistic equation have been proposed
previously [26–29]. Arrested cells (M(t,a)) are assumed to
compete for space with proliferating cells so that T(t) is the total
(proliferating+arrested) number of cancer cells at time t. The
parameters lN and K are chosen by fitting time-courses of cell
numbers to data from untreated tumor xenografts in [13], as
shown in Figure 1C (black curve).
We account for the regulation of cell death by the Bcl-2 family
of proteins in the following way. For simplicity, and in the absence
of appropriate experimental data, we represent each of the pro-
and anti-apoptotic sub-families of the Bcl-2 family by single
variables. Given the specificity of ABT-737 for Bcl-2 and Bcl-xL,
and its similar binding affinity for both these molecules [30], we
represent the anti-apoptotic members of the Bcl-2 family by Bcl-
xL. Further, Bax is taken to represent the pro-apoptotic proteins
since it is the members of the Bax-like subfamily which controls the
release of cytochrome c from the mitochondria that leads to
caspase activation, that is followed by cell death [7]. The rate of
cell death dN (X ) is consequently assumed to be an increasing
function of free intracellular Bax (X (t)).
Pharmacologic therapy is applied periodically in the form of
ABT-737 or carboplatin, alone or in combination. ABT-737
increases the rate of cell death dN , while carboplatin induces DNA
damage and subsequent cell arrest at a rate aC(CT ), which
depends on tissue carboplatin concentration CT (t). The final term
in Equation A represents the rate at which arrested cells recover
and return to the proliferating pool.
We now describe the effect on the growing tumor of the
application of carboplatin and ABT-737.
Effect of ABT-737 on Proliferating Cells. Upon applica-
tion, ABT-737 enters the proliferating tumor cells where it binds
to, and occupies Bcl-xL (see Figure 1B). This results in a build-up
of free Bax that was previously sequestered in the form of Bcl-
xLBax heterodimers, thereby increasing the rate of cell death.
Parameters relating to the death rate dN of proliferating cells are
chosen by fitting time-courses of estimated cell numbers to tumor
xenograft growth inhibition data taken from [13], wherein
IGROV-1 xenografts established in mice were treated daily with
a fixed dose of ABT-737 administered intraperitoneally for 4
weeks. The best fit is shown in Figure 1C (red curve). The reaction
diagram in Figure 1B representing ABT-737 pharmacodynamics
is translated into a system of ordinary differential equations using
the principle of mass balance.
Effect of Carboplatin on Proliferating Cells. The cyto-
toxicity of carboplatin is primarily due to damage induced by the
formation of intra- and interstrand adducts at the nucleophilic N7
sites in the DNA. This damage stimulates the activation of
downstream pathways that lead to cell cycle arrest, followed by
either survival if the DNA damage is repairable, or apoptosis [6].
Consequently, upon drug application, proliferating cells are
assumed to undergo cell cycle arrest at a rate aC that is assumed
to be an increasing and saturating function of the tissue
carboplatin concentration, CT (t), so that as the drug dose (and
correspondingly the level of DNA damage) increases, the rate of
cell cycle arrest also increases up to a maximum level.
An Age-structured Model of Arrested Cell Dynamics
The arrested cells are removed to a separate compartment,
where they either undergo apoptosis or recover and return to the
proliferating population (a schematic is shown in Figure 1A). In
[13], the initiation of apoptosis was routinely observed in cells 12–
16 hours post carboplatin administration. Consequently, arrested
cell dynamics are described by the following partial differential
equation derived by applying the general McKendrick equation
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Here the rate of arrested cell death dM is taken to be a function
of the time a for which the cells have been arrested. Cell
cytotoxicity has been found to correlate linearly with the amount
of platinum bound to the DNA, and hence the extent of DNA
damage [6]. Accordingly, the rate of arrested cell death is taken to
be linearly proportional to CT (t{a), the amount of tissue
carboplatin at the time of cell-cycle arrest. Next, as in the case
of proliferating cells, when ABT-737 is co-administered with
carboplatin, it is taken up by the arrested cells where it binds to,
and occupies Bcl-xL (see Figure 1B), causing a build-up of free
Bax, X (t). Further, in [14] the observed synergy between
carboplatin and ABT-737 was shown to be due to an increased
dependence of DNA-damaged cells on Bcl-xL for survival.
Accordingly, the rate of arrested cell death dM is taken also to
be proportional (with constant of proportionality rs) to X (t). rs is
an important parameter in our model: it represents the sensitivity
of the arrested cells to changes in Bax, and hence provides a
quantitative measure of the degree of synergy between carboplatin
and ABT-737. Equation B is solved subject to the boundary
condition:
M(t,0)~aC(CT )N,
which represents the rate of cell arrest (see Equation A). Finally,
the length of time for which a cell can remain in an arrested state is
limited. We therefore assume that cells that have not undergone
apoptosis after a characteristic time ar~48 hours recover and
return to the proliferating population, this return being instanta-
neous so that M(t,a)~0 for awar. Additionally, the number of




Parameters relating to the rate at which proliferating cells
become growth arrested aC and the rate at which arrested cells die
dM are chosen by fitting time-courses of estimated numbers of cells
to tumor xenograft growth inhibition data taken from [13],
wherein IGROV-1 xenografts established in mice were treated
weekly with a fixed dose of carboplatin administered intravenously
for 4 weeks as a single agent, or in combination with a fixed daily
dose of ABT-737. The best fits are shown in Figure 1D.
The functional forms used in our model for the response of
proliferating and arrested cells to carboplatin and ABT-737 also
account for their pharmacokinetics, which are described below.
Carboplatin Pharmacokinetics
Carboplatin was administered intraperitoneally on a weekly
schedule in [13] and its pharmacokinetics are assumed to be
governed by the following 3-comparment model. Experimental
evidence suggests that small molecular weight drugs (molecular
weight of carboplatin = 371.2 Da [32]) delivered intraperitoneally
are readily absorbed through the peritoneal vasculature to enter
systemic circulation [33,34]. Consequently, the peritoneal cavity is
taken to be the first compartment. Since the time-activity curve of
carboplatin in the blood plasma of mice has been shown to be
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biphasic [32], the circulatory system together with highly
vascularized and well-perfused organs are taken to be the second
or central compartment, and the peripheral organs and tissues
with relatively poor vascular perfusion account for the third
compartment. As tumor vasculature is characterized by its poor
functional quality, and is highly disorganized [35], we assume that
the tumor resides in the peripheral pharmacokinetic compartment
of carboplatin. Details regarding carboplatin pharmacokinetics
and pharmacodynamics are provided in section S3 in File S1 and
Figure S2. Related parameter values are provided in Table S3.
We investigate the effect on tumor response of administering the
same dose of carboplatin as either a rapid infusion or bolus, or a
continuous infusion lasting several hours, when given in combi-
nation with ABT-737. In fact, the time of infusion (Ti) of each
dose of carboplatin is predicted to be a critical parameter in
determining the therapeutic efficacy of combination therapy.
ABT-737 Pharmacokinetics
ABT-737 was administered intraperitoneally on a daily
schedule in [13] and its pharmacokinetics are assumed to be
governed by the following 3-comparment model. Since ABT-737
is a low molecular weight drug (molecular weight = 813.4 Da
[24]), as in the case of carboplatin, the peritoneal cavity is taken
as the first compartment, and the systemic circulation as the
central (and second) compartment. In our model, we explicitly
account for the regulation of cell death by the Bcl-2 family of
proteins. Therefore, a third intracellular compartment, into
which the drug permeates from the systemic circulation, is
included. Details regarding ABT-737 pharmacokinetics and the
intracellular regulation of cell death are provided in section S2 in
File S1 and Figure S1. Related parameter values are provided in
Tables S1 and S2.
We remark that given that the circulation half-life of ABT-737 is
several hours (see File S1), administering it daily ensures that
carboplatin-arrested cells are exposed to it, irrespective of the time
of cell arrest.
The emergence of carboplatin-resistance. When consid-
ering the emergence of resistance to carboplatin, the proliferating
cell population is subdivided into two classes - carboplatin-sensitive
and carboplatin-resistant. Following [13] where ovarian cancer
cell lines with different sensitivities to carboplatin were observed to
be comparably responsive to ABT-737, both carboplatin-sensitive
and resistant cells are assumed to be equally sensitive to ABT-737.
Model Parametrization and Simulation
Details of parameter estimation described in this section, and a
list of parameter values can be found in section S5 in File S1 and
Table S4. All model simulations are carried out in Matlab, a
technical computing language, the numerical methods being
described in Section S4 of the supplemental File S1. Figure S3
shows typical model simulations. A sensitivity analysis on the
estimated parameter values can be found in Figure S4 and section
S5 of the supplemental File S1.
Supporting Information
Figure S1 ABT-737 pharmacokinetics in a mouse. A,
ABT-737 is periodically administered intraperitoneally (i.p.), into
the peritoneal cavity from where it enters the systemic circulation.
From here, ABT-737 enters the intracellular compartment, and is
also cleared from the body. Figures showing B, intraperitoneal, C,
plasma and D, intracellular ABT-737 concentration time-courses
when 100 mg/kg of the drug is administered daily starting on day
5. E, Resultant intracellular Bcl-xL (black curve) and Bax (red
curve) concentration time-courses.
(TIF)
Figure S2 Carboplatin pharmacokinetics in a mouse. A,
Carboplatin is periodically administered intraperitoneally (i.p.),
into the peritoneal cavity from where it enters the systemic
circulation. From here, carboplatin is distributed to peripheral
organs and tissues with poor vascular perfusion, and is also cleared
from the body. Figures showing plasma (black curve) and
peripheral tissue (red curve) carboplatin concentration time-
courses corresponding to a dose of 30 mg/kg, given B, as a bolus,
or C, as a continuous infusion lasting 12 hours.
(TIF)
Figure S3 Tumor xenograft response to 30 mg/kg of
carboplatin-only therapy. Carboplatin administration as a
bolus dose every 7 days, starting on day 19 (black arrow) is
simulated. Figure shows total cell number (red curve) and total cell
number averaged over the period of therapy administration (black
curve) versus time.
(TIF)
Figure S4 Parameter sensitivity analysis. A–E, Model
sensitivity to key parameters. Variation of the parameters from
their baseline values is plotted on the x-axis. The % change in the
Euclidean norm of the error over its value from performing fits of
the model to experimental data (see Figures 1B,C in main
manuscript) is plotted on the y-axis. F, Predicted average total
(black curve), proliferating (red curve) and growth arrested (blue
curve) tumor cell numbers at the end of 4 weeks of treatment of a
tumor xenograft with 30 mg/kg carboplatin administered weekly,
as the time of infusion of each dose is varied.
(TIF)
File S1 Supplementary Information. Section S1: Model
Equations. Section S2: ABT-737 Pharmacokinetics and
the Intracellular Regulation of Cell Death. Section S3:
Carboplatin Pharmacokinetics. Section S4: Simulation
Methodology. Section S5: Parameter Estimation for
Monoclonal Tumor Xenograft Growth Treatment.
(PDF)
Table S1 List of parameter values relating to ABT-737
pharmacokinetics and pharmacodynamics.
(PDF)
Table S2 List of non-dimensional parameter values
relating to ABT-737 pharmacokinetics and pharmaco-
dynamics.
(PDF)
Table S3 List of parameter values relating to carbo-
platin pharmacokinetics.
(PDF)
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